As biotech advances, the gap between discovery and approval leaves patients with rare diseases staring at a desperate window. Montana’s recent legislative expansions aim to bridge that gap, offering a controversial but vital pathway to unproven treatments.

The Race Against Biological Plasticity

For families grappling with rare genetic disorders, time is everything. Take three-year-old Brody DeVault, who lives with creatine transporter deficiency (CTD). The disorder blocks energy from reaching his brain and muscles, causing severe neurological delays and muscle weakness.

During early childhood, neuroplasticity—the brain’s prime window for forming new connections—offers the best chance for recovery. If Brody waits years for a drug to clear Phase II and Phase III trials, he may miss that window entirely, rendering any later treatment ineffective.

Breaking the Regulatory Bottleneck

French biotech firm Ceres Brain Therapeutics is developing a nasal spray that bypasses the creatine transport problem and delivers energy straight to the brain. The spray showed promise in mice and completed a Phase I trial with 48 healthy adults, yet U.S. patients cannot access it.

Because the product is not registered with the FDA and its manufacturing process fails to meet U.S. standards, Ceres cannot use expanded-access programs. The result: a potentially life-changing therapy sits idle while patients wait.

Montana’s Legislative Pivot

Montana is trying to untangle that knot. The state’s original “Right to Try” law, passed in 2015, helped terminally ill patients. In 2023 the law expanded to include non-terminal patients, provided the experimental drug has cleared Phase I.

Key components now include:

  • Experimental Treatment Review Board (ETRB): Reviews applications for unapproved drugs.
  • Clinical Framework: Department of Health and Human Services rules that spell out how clinics may legally sell and administer these treatments.
  • Pragmatic Access: Allows companies like Ceres to sell therapies through Montana-based clinics, sidestepping some federal hurdles.

The Conflict Between Innovation and Oversight

Biotech leaders, including Ceres CEO Thomas Joudinaud, hesitate to join state-run programs for fear of FDA retaliation. Companies that participate risk penalties or delays when they later seek formal approval.

Bioethicists warn that Phase I trials only assess safety in healthy adults, not efficacy in sick patients. Families eye “offshore” medical zones in places like Honduras to dodge the bottleneck, sparking a debate: should regulatory safety trump individual autonomy for terminal or degenerative conditions?

Key Takeaways

  • Expanded Eligibility: Montana now permits non-terminal patients to access drugs that have cleared Phase I.
  • The Plasticity Window: Delays from traditional trials can cause irreversible developmental loss for neurological disorders.
  • Regulatory Uncertainty: State-level “Right to Try” initiatives clash with the FDA’s authority to approve and enforce drug safety.

Who Wins, Who Loses

The FDA retains its mandate to protect public health.

Bottom Line

Montana’s expansion of its Right-to-Try law opens a narrow but significant door for patients with non-terminal, rare diseases to obtain experimental therapies that have only cleared an early safety hurdle. The move pits state ambition against federal oversight, forcing companies, regulators, and families to weigh early-treatment promise against unproven efficacy and possible legal repercussions. The outcome will shape how the United States balances rapid access with the safeguards built into its drug-approval system.